Skip to main content
Figure 6 | Lipids in Health and Disease

Figure 6

From: In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor

Figure 6

Incorporation of [13C 6 ]palmitic acid and [13C 3 ]glycerol (*) from PPI-1038 (100 mg/kg/day for 3 days) into PlsEtn 16:0/22:6 in the neocortex and eyes of Pex7 mice. Similarly the incorporation of [13C3]DHA (**) into PlsEtn 16:0/22:6, PlsEtn 18:0/22:6 and PlsEtn 18:1/22:6 is presented. N = 4. Mean ± SD. Increases in labeling in the Pex7 mice were significant in all cases (p < 0.01). HT, heterozygote controls; HO, homozygotes. * = [13C16]palmitic acid + [13C3]glycerol labeled PlsEtn x/22:6; ** = [13C3]DHA labeled PlsEn x/22:6.

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X